Acorda Therapeutics Launches New Interactive Website Spotlighting Treatment with Ampyra® (Dalfampridine) of Walking Problems in Patients with Multiple Sclerosis

New site – – is first to focus exclusively on walking problems for people living with MS, with patient profiles, medical information, and opportunities for visitors to post messages of inspiration to help others.


Acorda Therapeutics, Inc. (Nasdaq: ACOR - News) today announced the launch of a new interactive patient website called Ampyra Journeys ( The site is the first-ever stand-alone patient site to focus on walking problems associated with multiple sclerosis (MS). Ampyra (dalfampridine) is an oral medication approved by the FDA as a treatment to improve walking in patients with multiple sclerosis. This was demonstrated by an increase in walking speed.